ClinicalTrials.gg
RecruitingNCT06830018Updated Feb 17, 2025

Nanocrystalline Megestrol for First-line Treatment of Advanced Gastric or Colorectal Cancer With Cancer-related Fatigue

An interventional study of Nano-crystalline Megestrol Acetate Oral Suspension and Standard Treatment in Cancer-related Fatigue, Gastric Cancer,Colorectal Cancer,Nano-crystalline Megestrol Acetate,Megestrol Acetate,First-line Treatment, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-02-17.

Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was expected by Jan 2026, 10 months ago, but the record still lists the study as recruiting.
  • Started Jan 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,136 studies in Colorectal Neoplasms with a site in China — 526 open to participants now, 603 under way, 67 of them phase 3. Colorectal Neoplasms · China.

Planned enrollment
461st of 891
76 · median 80
Started
2025
with 124 others
No phase
150 of 1,136
81 open now
Primary completion
2026-01
later than 195 of 602 live
Registered
867th of 1,136
by date

Among the 1,136 studies in Colorectal Neoplasms with a site in China, this one is the 461st largest by planned enrollment of the 891 interventional ones that give a count, is one of 125 that started in 2025, is one of 150 with no phase, reaches primary completion later than 195 of the 602 other live ones, and was the 867th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

526 of the 1,136 studies in Colorectal Neoplasms with a site in China are open now. Recruiting first, the newest first:

521 more — sign in →

All 526 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,136 studies in Colorectal Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study is a prospective, randomized, parallel-controlled clinical trial, with the primary objective to evaluate the efficacy and safety of nano-crystalline megestrol acetate combined with standard treatment compared to standard treatment alone for the first-line treatment of patients with cancer-related fatigue in gastric or colorectal cancer.

03

Conditions studied

  • Cancer-related Fatigue, Gastric Cancer,Colorectal Cancer,Nano-crystalline Megestrol Acetate,Megestrol Acetate,First-line Treatment

Keywords

  • cancer-related fatigue, cancer-caused fatigue,fatigue,appetite stimulants
  • gastric cancer,colorectal cancer,gastrointestinal tumor,cancer,tumor,carcinoma,
  • nano-crystalline megestrol acetate,megestrol,megestrol acetate,
  • antineoplastic agents, hormonal,central nervous system stimulants,appetite stimulants
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years and ≤75 years.
  • (ECOG) physical status score of 0-2.
  • Expected survival ≥ 6 months.
  • Locally advanced or gastric/gastroesophageal junction (G/GEJ) adenocarcinoma or colorectal adenocarcinoma not amenable to radical treatment with histologic or cytologic confirmation.
  • No prior systemic systemic antitumor therapy for gastric/gastroesophageal junction (G/GEJ) adenocarcinoma or colorectal cancer.
  • Have at least one measurable tumor lesion according to v1.1.
  • Compliance with a Fatigue Visual Analog Scale (VAS) score of ≥ 4 (consistent with moderate or severe fatigue).
  • Complain of anorexia.
  • Good organ function as determined by the following requirements.

Exclusion criteria

Exclusion Criteria:

  • Suffered significant surgery or traumatic injuries within the past 1month.
  • Having any condition that affects gastrointestinal absorption, such as dysphagia, malabsorption, or uncontrollable vomiting.

currently undergoing tube feeding or parenteral nutrition.

  • Suffering from anorexia due to neurosis, mental illness, or difficulty eating due to pain.
  • Received erythropoietin or blood transfusion within the past 1month.
  • Comorbidities such as serious cerebrovascular, heart, kidney, or liver disease.
  • A history of to the components of the trial medication.
  • Other conditions that were considered inappropriate as determined by the investigators.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
76 participants (estimated)

Study arms

  • Experimental
    Nano-crystalline Megestrol Acetate Oral Suspension + Standard Therapy

    Drug: Nano-crystalline Megestrol Acetate Oral Suspension · Combination Product: Standard Treatment

  • Active comparator
    Standard Therapy

    Combination Product: Standard Treatment

Interventions

  • Nano-crystalline Megestrol Acetate Oral Suspension, with a specification of 125 mg/mL, the study group takes 5 mL orally per day (625 mg/day), and continues medication; after completing the treatment cycle, patients who are assessed by the researchers as suitable for continued treatment may continue to receive therapy.

  • Combination productStandard Treatment

    Standard Treatment,First-line treatment (chemotherapy + immunotherapy/targeted therapy)

06

What researchers measure

Primary outcomes

  1. the difference in improvement of fatigue as measured with the Revised Piper Fatigue Scale-Chinese Version (RPFS-CV).

    Time frame: week 6

  2. the difference in improvement of appetite based on A/CS-12 assessment

    Time frame: week 6

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Jan 2026, 12 months after the start.

Of 57 industry-sponsored interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 37. This study's planned 12 months is below that.

Counting every sponsor, half of 956 studies reached it within 31 months; a quarter within 14 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2025
First posted
Feb 17, 2025
StartActual
Jan 23, 2025
Primary completionEst.
Jan 2026
CompletionEst.
Jul 2026
Last update
Feb 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06830018
Responsible party
Sponsor
First posted
Feb 17, 2025
Start date
Jan 23, 2025
Primary completion
Jan 2026 (estimated)
Completion
Jul 2026 (estimated)
Last update
Feb 17, 2025

Study contacts

Xiujuan Qu
Contact
xjqu@cmu.edu.cn
024-83281560

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Megestrol Acetate

Start the discussion